Why the study?
Does inhibition of initial platelet adherence with PGI2 or dipyridamole influence the development of nonthrombogenicity in injured rabbit aortas?
Does inhibition of initial platelet adherence with PGI2 or dipyridamole influence the development of nonthrombogenicity in injured rabbit aortas?
Injured vessel walls can develop a nonthrombogenic surface over approximately 8 hours even when initial platelet adherence is pharmacologically prevented.
Answers are grounded in this paper and cite their sources.
Supports vessel passivation after platelet inhibition in rabbit injury models; leaves open translation to human antithrombotic strategies.
After removal of the endothelium from normal rabbit aortas or after injury to the neointima, the injured surfaces rapidly become nonreactive to circulating platelets. Experiments were done to determine whether prevention of the initial interaction of platelets with the surfaces would influence the loss of vessel wall reactivity. Inhibition of platelet accumulation on the subendothelium by the infusion of PGI2 (850 ng/kg/min) or the administration of dipyridamole (12.5 mg/kg initially followed by 5 mg/kg/hr) for periods of less than 8 hours inhibited platelet accumulation of platelets on the surfaces when the infusions were stopped. If the animals were treated for 8 hours, platelets did not accumulate on the surface when the drugs were discontinued. Thus, an injured vessel wall can develop a nonthrombogenic surface even when platelet adherence is prevented, although approximately 8 hours are required before the surface loses its ability to interact with platelets.
No takes yet. Share an insight, caveat, or question.
Groves et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: